08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

GUB Unternehmensbeteiligungen GmbH & Co. KGaA, VC Fonds Berlin GmbH, BioGenes deal

Immunoassay and antibody developer BioGenes bought out all outstanding shares of the company from investors GUB Unternehmensbeteiligungen and VC Fonds for an undisclosed sum. GUB and BioGenes declined to disclose details, and VC Fonds could...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

BioGenes GmbH, Cellmid sales and marketing update

Cellmid launched BioGenes' MK ELISA globally for research use to measure midkine ( MDK ; MK) in blood serum. The company said MDK has been found to correlate with cancer progression and malignancy. BioGenes GmbH...